122 related articles for article (PubMed ID: 22257229)
1. [Positron emission tomography in the diagnosis and monitoring of patients with nonseminomatous germ cell tumours].
Büchler T; Simonová K; Fencl P; Abrahámová J
Klin Onkol; 2011; 24(6):413-7. PubMed ID: 22257229
[TBL] [Abstract][Full Text] [Related]
2. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M;
J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography.
Buchler T; Simonova K; Fencl P; Jarkovsky J; Abrahamova J
Cancer Invest; 2012 Jul; 30(6):487-92. PubMed ID: 22506657
[TBL] [Abstract][Full Text] [Related]
4. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
[TBL] [Abstract][Full Text] [Related]
5. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
[TBL] [Abstract][Full Text] [Related]
6. PET in testicular cancer.
Becherer A
Methods Mol Biol; 2011; 727():225-41. PubMed ID: 21331937
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
8. [Positron emission tomography in germ cell tumors in men : Possibilities and limitations].
Schriefer P; Hartmann M; Oechsle K; Meyer CP; Klutmann S; Fisch M; Bokemeyer C; Oing C
Urologe A; 2019 Apr; 58(4):418-423. PubMed ID: 30374517
[TBL] [Abstract][Full Text] [Related]
9. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients.
Cremerius U; Wildberger JE; Borchers H; Zimny M; Jakse G; Günther RW; Buell U
Urology; 1999 Nov; 54(5):900-4. PubMed ID: 10565755
[TBL] [Abstract][Full Text] [Related]
10. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET.
Nuutinen JM; Leskinen S; Elomaa I; Minn H; Varpula M; Solin O; Söderström KO; Joensuu H; Salminen E
Eur J Cancer; 1997 Jul; 33(8):1234-41. PubMed ID: 9301449
[TBL] [Abstract][Full Text] [Related]
11. The role of
Hung TJ; McLean L; Mitchell C; Pascoe C; Lawrentschuk N; Murphy DG; Iravani A; Singh D; Hofman MS; Zidan L; Akhurst T; Lewin J; Hicks RJ
Cancer Imaging; 2019 May; 19(1):28. PubMed ID: 31142361
[TBL] [Abstract][Full Text] [Related]
12. PET imaging in the management of tumors of testis and ovary: current thinking and future directions.
Basu S; Rubello D
Minerva Endocrinol; 2008 Sep; 33(3):229-56. PubMed ID: 18846028
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Metastatic Seminomatous Testicular Tumor with Complicated Diagnosis by FDG-PET].
Hashizume A; Mizuno N; Kawai M; Kishida T
Hinyokika Kiyo; 2016 Jul; 62(7):383-7. PubMed ID: 27569358
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography in the diagnosis and management of intracranial germ cell tumours.
Kelly PA; Metcalfe K; Evanson J; Sabin I; Plowman PN; Monson JP
Horm Res; 2009; 72(3):190-6. PubMed ID: 19729952
[TBL] [Abstract][Full Text] [Related]
15. Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.
Joice GA; Rowe SP; Gorin MA; Pierorazio PM
Curr Urol Rep; 2018 Nov; 19(12):110. PubMed ID: 30413968
[TBL] [Abstract][Full Text] [Related]
16. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET in the management of germ cell tumor.
De Giorgi U; Pupi A; Fiorentini G; Rosti G; Marangolo M
Ann Oncol; 2005 May; 16 Suppl 4():iv90-94. PubMed ID: 15923438
[TBL] [Abstract][Full Text] [Related]
18. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications].
Maszelin P; Lumbroso J; Theodore C; Foehrenbach H; Merlet P; Syrota A
Prog Urol; 2000 Dec; 10(6):1190-9. PubMed ID: 11217558
[TBL] [Abstract][Full Text] [Related]
19. Is positron emission tomography reliable to predict post-chemotherapy retroperitoneal lymph node involvement in advanced germ cell tumors of the testis?
Akbulut Z; Canda AE; Atmaca AF; Caglayan A; Asil E; Balbay MD
Urol J; 2011; 8(2):120-6. PubMed ID: 21656470
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography and clinical predictors of survival in primary extragonadal germ cell tumors.
Buchler T; Dusek P; Brisuda A; Simonova K; Fencl P; Jarkovsky J; Babjuk M; Abrahamova J
Klin Onkol; 2012; 25(3):178-83. PubMed ID: 22724566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]